Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors

Blood - Tập 100 - Trang 3155-3163 - 2002
Nicole M. Haynes1, Joseph A. Trapani1, Michèle W.L. Teng1, Jacob T. Jackson1, Loretta Cerruti1, Stephen M. Jane1, Michael H. Kershaw1, Mark J. Smyth1, Phillip K. Darcy1
1Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, and the Rotary Bone Marrow Research Laboratory, Royal Melbourne Hospital Research Foundation, Victoria, Australia.

Tóm tắt

AbstractTumor cells are usually weakly immunogenic as they largely express self-antigens and can down-regulate major histocompatability complex/peptide molecules and critical costimulatory ligands. The challenge for immunotherapies has been to provide vigorous immune effector cells that circumvent these tumor escape mechanisms and eradicate established tumors. One promising approach is to engineer T cells with single-chain antibody receptors, and since T cells require 2 distinct signals for optimal activation, we have compared the therapeutic efficacy of erbB2-reactive chimeric receptors that contain either T-cell receptor zeta (TCR-ζ) or CD28/TCR-ζ signaling domains. We have demonstrated that primary mouse CD8+ T lymphocytes expressing the single-chain Fv (scFv)–CD28-ζ receptor have a greater capacity to secrete Tc1 cytokines, induce T-cell proliferation, and inhibit established tumor growth and metastases in vivo. The suppression of established tumor burden by cytotoxic T cells expressing the CD28/TCR-ζ chimera was critically dependent upon their interferon gamma (IFN-γ) secretion. Our study has illustrated the practical advantage of engineering a T-cell signaling complex that codelivers CD28 activation, dependent only upon the tumor's expression of the appropriate tumor associated antigen.

Tài liệu tham khảo

Garrido, 1993, Natural history of HLA expression during tumour development., Immunol Today., 14, 491, 10.1016/0167-5699(93)90264-L Speiser, 1997, Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy., J Exp Med., 186, 645, 10.1084/jem.186.5.645 Hellstrom, 1997, Cancer vaccines: challenges and potential solutions., Mol Med Today., 3, 286, 10.1016/S1357-4310(97)01048-4 Eshhar, 1993, Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors., Proc Natl Acad Sci U S A., 90, 720, 10.1073/pnas.90.2.720 Hwu, 1993, Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain., J Exp Med., 178, 361, 10.1084/jem.178.1.361 Darcy, 2000, Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL., J Immunol., 164, 3705, 10.4049/jimmunol.164.7.3705 Haynes, 2001, Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma., J Immunol., 166, 182, 10.4049/jimmunol.166.1.182 Greenfield, 1998, CD28/B7 costimulation: a review., Crit Rev Immunol., 18, 389, 10.1615/CritRevImmunol.v18.i5.10 Brocker, 1995, Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes., J Exp Med., 181, 1653, 10.1084/jem.181.5.1653 Dustin, 1999, Costimulation: building an immunological synapse., Science., 283, 649, 10.1126/science.283.5402.649 Viola, 1999, T lymphocyte costimulation mediated by reorganization of membrane microdomains., Science., 283, 680, 10.1126/science.283.5402.680 Liebowitz, 1998, Costimulatory approaches to adoptive immunotherapy., Curr Opin Oncol., 10, 533, 10.1097/00001622-199811000-00010 Renner, 1994, Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells., Science., 264, 833, 10.1126/science.8171337 Krause, 1998, Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes., J Exp Med., 188, 619, 10.1084/jem.188.4.619 Finney, 1998, Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product., J Immunol., 161, 2791, 10.4049/jimmunol.161.6.2791 Hombach, 2001, T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis., Cancer Res., 61, 1976 Eshhar, 2001, Functional expression of chimeric receptor genes in human T cells., J Immunol Methods., 248, 67, 10.1016/S0022-1759(00)00343-4 Geiger, 2001, Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes., Blood., 98, 2364, 10.1182/blood.V98.8.2364 Maher, 2002, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor., Nat Biotechnol., 20, 70, 10.1038/nbt0102-70 Hellstrom, 1995, Can co-stimulated tumor immunity be therapeutically efficacious?, Immunol Rev., 145, 123, 10.1111/j.1600-065X.1995.tb00079.x Wels, 1992, Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor., Cancer Res., 52, 6310 Evan, 1985, Isolation of monoclonal antibodies specific for human c-myc proto- oncogene product., Mol Cell Biol., 5, 3610, 10.1128/MCB.5.12.3610 Stein, 1994, The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3′-kinase., Mol Cell Biol., 14, 3392, 10.1128/MCB.14.5.3392 Alvarez-Vallina, 1996, Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors., Eur J Immunol., 26, 2304, 10.1002/eji.1830261006 Thompson, 1989, CD28 activation pathway regulates the production of multiple T-cell- derived lymphokines/cytokines., Proc Natl Acad Sci U S A., 86, 1333, 10.1073/pnas.86.4.1333 Sgadari, 1996, Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10., Blood., 87, 3877, 10.1182/blood.V87.9.3877.bloodjournal8793877 Geiger, 2001, Development and application of receptor-modified T lymphocytes for adoptive immunotherapy., Transfus Med Rev., 15, 21, 10.1053/tmrv.2001.19949 Spiess, 1987, In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2., J Natl Cancer Inst., 79, 1067 Rosenberg, 1986, A new approach to the adoptive immunotherapy of cancer with tumor- infiltrating lymphocytes., Science., 233, 1318, 10.1126/science.3489291 Hwu, 1995, In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes., Cancer Res., 55, 3369 Kagi, 1994, Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice., Nature., 369, 31, 10.1038/369031a0 Boehm, 1997, Cellular responses to interferon-gamma., Annu Rev Immunol., 15, 749, 10.1146/annurev.immunol.15.1.749 Dighe, 1994, Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors., Immunity., 1, 447, 10.1016/1074-7613(94)90087-6 Kaplan, 1998, Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice., Proc Natl Acad Sci U S A., 95, 7556, 10.1073/pnas.95.13.7556 Nakajima, 2001, A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice., Cancer Res., 61, 3399 Billiau, 1998, Immunomodulatory properties of interferon-gamma: an update., Ann N Y Acad Sci., 856, 22, 10.1111/j.1749-6632.1998.tb08309.x Coughlin, 1998, Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis., J Clin Invest., 101, 1441, 10.1172/JCI1555 Coughlin, 1998, Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis., Immunity., 9, 25, 10.1016/S1074-7613(00)80585-3 Nagoshi, 1998, Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes., J Immunol., 160, 334, 10.4049/jimmunol.160.1.334 Wing, 1989, Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients., Blood., 73, 643, 10.1182/blood.V73.3.643.643 Lenschow, 1996, CD28/B7 system of T cell costimulation., Annu Rev Immunol., 14, 233, 10.1146/annurev.immunol.14.1.233 Kessels, 2001, Immunotherapy through TCR gene transfer., Nat Immunol., 2, 957, 10.1038/ni1001-957 Badovinac, 2000, Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma., Science., 290, 1354, 10.1126/science.290.5495.1354 Su, 1994, JNK is involved in signal integration during costimulation of T lymphocytes., Cell., 77, 727, 10.1016/0092-8674(94)90056-6 Barz, 1998, Mutational analysis of CD28-mediated costimulation of Jun-N-terminal kinase and IL-2 production., J Immunol., 161, 5366, 10.4049/jimmunol.161.10.5366 Dustin, 2001, Environmental control of immunological synapse formation and duration., Trends Immunol., 22, 192, 10.1016/S1471-4906(01)01872-5 Stanislawski, 2001, Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer., Nat Immunol., 2, 962, 10.1038/ni1001-962 Semino, 1999, Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience., Anticancer Res., 19, 5645
Thông tin
Thông tin xuất bản

Blood

Tập 100

3155-3163

Thông tin tác giả